Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $81.29.

GPCR has been the topic of a number of recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Morgan Stanley began coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company.

Structure Therapeutics Trading Down 0.5 %

NASDAQ GPCR opened at $27.04 on Thursday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -36.54 and a beta of -2.78. The business’s 50 day moving average is $32.63 and its two-hundred day moving average is $36.70. Structure Therapeutics has a 12-month low of $25.90 and a 12-month high of $62.74.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Sandia Investment Management LP acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $39,000. GAMMA Investing LLC increased its position in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the last quarter. Quarry LP purchased a new stake in shares of Structure Therapeutics in the second quarter valued at $79,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after acquiring an additional 1,420 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.